SI2445522T1 - Imunogeni sestavki antigenov Staphylococcusa aureusa - Google Patents

Imunogeni sestavki antigenov Staphylococcusa aureusa

Info

Publication number
SI2445522T1
SI2445522T1 SI201031533T SI201031533T SI2445522T1 SI 2445522 T1 SI2445522 T1 SI 2445522T1 SI 201031533 T SI201031533 T SI 201031533T SI 201031533 T SI201031533 T SI 201031533T SI 2445522 T1 SI2445522 T1 SI 2445522T1
Authority
SI
Slovenia
Prior art keywords
staphylococcus aureus
immunogenic compositions
aureus antigens
antigens
immunogenic
Prior art date
Application number
SI201031533T
Other languages
English (en)
Inventor
Annaliesa Anderson
Viliam Pavliak
Kathrin Ute Jansen
Ingrid Lea Dodge
Steven Morris Baker
Jasdeep Singh Nanra
Ellen Murphy
Bruce Arthur Green
Mark Edward Ruppen
Yekaterina Timofeyeva
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of SI2445522T1 publication Critical patent/SI2445522T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
SI201031533T 2009-06-22 2010-06-22 Imunogeni sestavki antigenov Staphylococcusa aureusa SI2445522T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21913409P 2009-06-22 2009-06-22
PCT/US2010/039510 WO2010151544A1 (en) 2009-06-22 2010-06-22 Immunogenic compositions of staphylococcus aureus antigens
EP10730296.0A EP2445522B1 (en) 2009-06-22 2010-06-22 Immunogenic compositions of staphylococcus aureus antigens

Publications (1)

Publication Number Publication Date
SI2445522T1 true SI2445522T1 (sl) 2017-10-30

Family

ID=42542752

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031533T SI2445522T1 (sl) 2009-06-22 2010-06-22 Imunogeni sestavki antigenov Staphylococcusa aureusa

Country Status (27)

Country Link
US (3) US8568735B2 (sl)
EP (2) EP2445522B1 (sl)
JP (3) JP5395264B2 (sl)
KR (1) KR101486122B1 (sl)
CN (2) CN107096020A (sl)
AR (2) AR078601A1 (sl)
AU (1) AU2010264538B2 (sl)
BR (1) BRPI1015567A2 (sl)
CA (1) CA2766629C (sl)
CO (1) CO6480925A2 (sl)
DK (1) DK2445522T3 (sl)
ES (1) ES2642076T3 (sl)
HU (1) HUE036372T2 (sl)
IL (1) IL217084B (sl)
MX (2) MX343111B (sl)
MY (1) MY169837A (sl)
NZ (1) NZ597154A (sl)
PE (2) PE20110023A1 (sl)
PL (1) PL2445522T3 (sl)
PT (1) PT2445522T (sl)
RU (1) RU2536981C9 (sl)
SA (1) SA110310528B1 (sl)
SG (3) SG10201707084SA (sl)
SI (1) SI2445522T1 (sl)
TW (1) TWI469789B (sl)
WO (1) WO2010151544A1 (sl)
ZA (1) ZA201200501B (sl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
JP2008513409A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
PL2414387T3 (pl) 2009-04-03 2016-06-30 Univ Chicago Kompozycje i sposoby związane z wariantami białka A (SpA)
PE20110023A1 (es) * 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
TW201544119A (zh) 2009-06-22 2015-12-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法
AU2010271582B2 (en) * 2009-07-15 2016-07-28 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
KR20130093084A (ko) 2010-07-02 2013-08-21 더 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
MX350170B (es) * 2010-12-22 2017-08-28 Wyeth Llc Composición inmunogénica estable de antígenos de staphylococcus aureus.
RS58190B2 (sr) * 2011-02-08 2021-08-31 Medimmune Llc Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene
CN105693865B (zh) 2011-06-01 2020-07-17 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
US10653757B2 (en) 2011-07-22 2020-05-19 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against Staphylococcus aureus
IN2014CN02152A (sl) * 2011-09-01 2015-09-04 Novartis Ag
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
US8859740B2 (en) 2012-10-26 2014-10-14 Sorrento Therapeutics Inc. Anti-infective binding proteins that bind AIP2
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
JP6591961B2 (ja) 2013-03-15 2019-10-16 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 真菌病原体および細菌病原体を処置するための組成物および方法
CA2913088A1 (en) * 2013-05-21 2014-11-27 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN103412122B (zh) * 2013-08-09 2015-06-24 安徽农业大学 同步检测金葡菌a型和g型肠毒素的基于多表位串联肽的间接竞争elisa方法
CN103951748B (zh) * 2014-04-18 2017-07-11 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌eLtaS蛋白的单克隆中和性抗体E4‑1的制备及其应用
CN103951749B (zh) * 2014-04-18 2017-07-11 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌eLtaS蛋白的单克隆中和性抗体E4‑2的制备及其应用
EP3229833A1 (en) * 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Method of treatment
JP2019507759A (ja) 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット
CN110290804A (zh) * 2016-10-03 2019-09-27 王锦堂 克雷伯氏肺炎杆菌的荚膜多糖疫苗
CN106544432A (zh) * 2016-11-08 2017-03-29 江苏大学 一种金黄色葡萄球菌耐药性和毒力快速检测方法及试剂盒
CN116870144A (zh) * 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same
US10774135B2 (en) 2017-12-22 2020-09-15 Sorrento Therapeutics, Inc. Variant antibodies that bind AIP2
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
JP7239509B6 (ja) * 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
RU2707922C1 (ru) * 2019-06-27 2019-12-02 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Рекомбинантная плазмидная ДНК pQE-30_P36GP12_GP57, обеспечивающая синтез рекомбинантного белка P36GP12 в клетках Escherichia coli, штамм бактерий Escherichia coli - продуцент рекомбинантного белка P36GP12, рекомбинантный белок P36GP12, обладающий способностью связывать липополисахариды Escherichia coli
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN111072775B (zh) * 2019-12-26 2021-08-20 成都欧林生物科技股份有限公司 抗MntC蛋白抗体及其应用和包含其的试剂盒
CN111138551A (zh) * 2020-01-15 2020-05-12 黑龙江八一农垦大学 一种预防金黄色葡萄球菌和白色念珠菌感染的atm融合蛋白的制备及应用
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134214A (en) 1977-08-05 1979-01-16 Merck & Co., Inc. Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US5189015A (en) 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
CA2047031A1 (en) 1990-07-19 1992-01-20 Stephen Marburg Peptide-polysaccharide-protein conjugate vaccines
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5635348A (en) 1990-10-05 1997-06-03 Hoffmann-La Roche Inc. Method and probes for identifying bacteria found in blood
AU681573B2 (en) 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
US5980908A (en) 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
PT635132E (pt) 1992-03-19 2001-03-30 Henry M Jackson Found Advanc M Anticorpos opsonicos amplamente reactivos que reagem com antigenios de estafilococos comuns
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
PT783520E (pt) 1994-09-21 2002-05-31 Henry M Jackson Found Advanc M Anticorpos opsonicos amplamente reactivos que reagem com antigenios de estafilococos comuns
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
JPH11514870A (ja) 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
US6593114B1 (en) 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1005564A4 (en) 1997-06-12 2003-04-23 Shinetsu Bio Inc MANUFACTURE OF NON-SPECIFIC BACTERIAL EXOPOLYSACCHARIDES IN A RECOMBINANT BACTERIAL HOST
EP1000076A1 (en) 1997-07-17 2000-05-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES HEXADECASACCHARIDE-PROTEIN CONJUGATE VACCINE FOR $i(SHIGELLA DYSENTERIAE) TYPE 1
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
EP2319931A1 (en) 1997-11-26 2011-05-11 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
MXPA01002119A (es) 1998-08-31 2003-03-27 Inhibitex Inc Vacunas multicomponentes.
WO2000012689A1 (en) 1998-08-31 2000-03-09 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
JP2002540074A (ja) 1999-03-19 2002-11-26 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
EP1173485A1 (en) 1999-05-03 2002-01-23 Medarex, Inc. Human antibodies to staphylococcus aureus
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
WO2001034809A2 (en) 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
EP1315699B1 (en) 2000-03-22 2013-01-02 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
TR200302015T4 (tr) 2000-06-08 2004-01-21 Intercell Biomedizinische Forschungs-Und Entwicklungs Ag İmüno-uyarıcı oligodeoksinükleotitler
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1377314B1 (en) 2001-01-26 2011-09-14 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
EP2339344A1 (en) 2001-06-15 2011-06-29 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA2351018A1 (en) 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
JP4404627B2 (ja) 2001-08-02 2010-01-27 ユニヴァーシティー オヴ シェフィールド 抗原性ポリペプチド
FR2828404B1 (fr) 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
WO2003076470A1 (en) 2002-03-05 2003-09-18 Inhibitex, Inc. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
PT1490409E (pt) 2002-03-26 2009-04-03 Novartis Vaccines & Diagnostic Sacáridos modificados possuindo uma estabilidade melhorada em água
TW200306314A (en) 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CN100351260C (zh) 2002-11-12 2007-11-28 布赖汉姆妇女医院 葡萄球菌感染的多糖疫苗
JP4078417B2 (ja) 2003-03-04 2008-04-23 独立行政法人産業技術総合研究所 好熱菌由来オリゴペプチダーゼ
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
DE602004024179D1 (de) 2003-03-31 2009-12-31 Intercell Ag Staphylococcus epidermidis antigene
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005058940A2 (en) 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
US7537766B2 (en) 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
GB0421079D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Immunogenic composition
JP2008513409A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP1802335A2 (en) 2004-10-21 2007-07-04 Wyeth a Corporation of the State of Delaware Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
SI1896065T2 (sl) 2005-06-27 2014-12-31 Glaxosmithkline Biologicals S.A. Postopek za pripravo cepiv
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
EP3141261A1 (en) * 2006-03-30 2017-03-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US8652480B2 (en) 2007-03-23 2014-02-18 Wyeth Llc Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharides
EA019516B1 (ru) 2008-01-31 2014-04-30 Де Провост, Феллоус Энд Сколарс Оф Де Колледж Оф Де Хоули Энд Андивайдид Тринити Оф Куин Элизабет, Неар Дублин Лечение микробных инфекций
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
PE20110023A1 (es) * 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
TW201544119A (zh) 2009-06-22 2015-12-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法
EP2453915B1 (en) 2009-07-16 2017-04-19 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Treatment of infections
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
MX350170B (es) 2010-12-22 2017-08-28 Wyeth Llc Composición inmunogénica estable de antígenos de staphylococcus aureus.

Also Published As

Publication number Publication date
EP2445522B1 (en) 2017-08-09
EP3238742A1 (en) 2017-11-01
KR101486122B1 (ko) 2015-01-23
AR119682A2 (es) 2022-01-05
CN102481352A (zh) 2012-05-30
CO6480925A2 (es) 2012-07-16
SG10201406520YA (en) 2014-11-27
RU2011151781A (ru) 2013-07-27
AR078601A1 (es) 2011-11-23
JP2012530786A (ja) 2012-12-06
TWI469789B (zh) 2015-01-21
RU2536981C9 (ru) 2015-05-10
US9114105B2 (en) 2015-08-25
CN107096020A (zh) 2017-08-29
IL217084B (en) 2018-11-29
TW201103557A (en) 2011-02-01
JP2013151501A (ja) 2013-08-08
PE20142188A1 (es) 2014-12-29
CA2766629A1 (en) 2010-12-29
BRPI1015567A2 (pt) 2021-08-31
HUE036372T2 (hu) 2018-07-30
US8889145B2 (en) 2014-11-18
PL2445522T3 (pl) 2018-01-31
PE20110023A1 (es) 2011-01-31
NZ597154A (en) 2013-10-25
CA2766629C (en) 2020-03-24
SA110310528B1 (ar) 2014-07-02
EP2445522A1 (en) 2012-05-02
US20120107327A1 (en) 2012-05-03
IL217084A0 (en) 2012-02-29
US20140017271A1 (en) 2014-01-16
MY169837A (en) 2019-05-16
JP6067806B2 (ja) 2017-01-25
JP5395264B2 (ja) 2014-01-22
AU2010264538A1 (en) 2012-01-19
SG10201707084SA (en) 2017-10-30
ZA201200501B (en) 2012-10-31
RU2536981C2 (ru) 2014-12-27
US8568735B2 (en) 2013-10-29
US20150132336A1 (en) 2015-05-14
PT2445522T (pt) 2017-10-04
JP5870052B2 (ja) 2016-02-24
JP2016034956A (ja) 2016-03-17
MX2012000044A (es) 2012-01-30
MX343111B (es) 2016-10-25
AU2010264538B2 (en) 2013-10-03
ES2642076T3 (es) 2017-11-15
KR20120046189A (ko) 2012-05-09
DK2445522T3 (en) 2017-09-25
SG176837A1 (en) 2012-01-30
WO2010151544A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
IL217084A0 (en) Immunogenic compositions of staphylococcus aureus antigens
HK1197370A1 (en) Stable immunogenic compositions of staphylococcus aureus antigens
IL215593A0 (en) Compositions for immunising against staphylococcus aureus
IL231104A0 (en) Helper assemblies of antigens for Staphylococcus aureus
EP2549993A4 (en) ANTIMICROBIAL COMPOSITIONS
ZA201300073B (en) Compositions comprising optical benefit agents
GB201003924D0 (en) Immunogenic composition
IL242592A (en) Immunogenic compounds
GB201015132D0 (en) Vaccine composition
EP2525818A4 (en) IMMUNOGENIC COMPOSITION OF INFLUENZA VIRUSES
HK1222343A1 (zh) -吡啶酮抗微生物合成物
EP2609931A4 (en) IMMUNOGENIC COMPOSITION
EP2605654A4 (en) ANTIMICROBIAL COMPOSITIONS
IL214127A0 (en) Vaccine compositions
IL220308A0 (en) Vaccine compositions
EP2640418A4 (en) IMMUNOGENIC COMPOSITIONS
ZA201301908B (en) Immunogenic compositions
GB0919690D0 (en) compositions for immunising against staphylococcus aureus
GB201111128D0 (en) Antimicrobial compositions
GB201013150D0 (en) Antimicrobial compositions
GB201010944D0 (en) Antimicrobial compositions
GB201003799D0 (en) Antimicrobial compositions
GB201002594D0 (en) Antimicrobial compositions
GB0900943D0 (en) Vaccine compositions
GB201003918D0 (en) Immunogenic composition